Forecasting Delayed Neurocognitive and Endocrine Toxicity from Radiation in Brain Tumor Patients
-
By
-
Kyle Tuohy
-
Aarav Badani
-
Ava Franklin
-
Brad Zacharia
-
Dawit Aregawi
-
Alireza Mansouri
-
Paul Brown
-
Michael Glantz
-
May 28, 2026
Clinical Scorecard: Forecasting Delayed Neurocognitive and Endocrine Toxicity from Radiation in Brain Tumor Patients
At a Glance
| Category | Detail |
|---|
| Condition | Radiation-induced neurocognitive dysfunction and endocrine dysfunction |
| Key Mechanisms | |
| Target Population | |
| Care Setting | |
Key Highlights
- No validated biomarkers exist to predict neurocognitive dysfunction prior to cranial irradiation.
Guideline-Based Recommendations
Diagnosis
Management
Monitoring & Follow-up
- Evaluate MRI for white matter changes at 6 months and assess serum lab values for endocrine function.
Risks
Patient & Prescribing Data
Adults with primary or metastatic brain tumors undergoing cranial irradiation.
Cranial irradiation is often combined with surgery and chemotherapy; specific radiation protocols vary by tumor type.
Clinical Best Practices
- Consider genetic counseling for patients regarding ApOE4 genotype.
Related Resources & Content
